Fabry disease
MONDO:0010526Fabry disease (FD) is a progressive, inherited, multisystemic lysosomal storage disease characterized by specific neurological, cutaneous, renal, cardiovascular, cochleo-vestibular and cerebrovascular manifestations.
Also known as: Alpha-galactosidase A deficiency, Anderson-Fabry disease, FD, Fabry disease, Fabry's disease, Fd, angiokeratoma corporis diffusum, diffuse angiokeratoma
96 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New oral drug shows promise for fabry disease in Long-Term trial
Disease control OngoingThis study looks at the long-term safety of a daily pill called lucerastat for adults with Fabry disease, a rare genetic disorder. About 107 people who completed a previous study will take the drug and be monitored for side effects over several years. The goal is to see if lucera…
Phase: PHASE3 • Sponsor: Idorsia Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill could protect hearts in rare genetic disease
Disease control OngoingThis phase 3 study tests whether venglustat, an experimental oral drug, can slow heart thickening better than current standard treatments in 104 adults with Fabry disease. Participants are randomly assigned to venglustat or usual care (enzyme replacement or migalastat) for 18 mon…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New enzyme therapy for fabry disease tested in Real-World setting
Disease control OngoingThis study follows 60 adults with Fabry disease who are receiving pegunigalsidase-alfa, a newer enzyme replacement therapy. Researchers want to see how well it works in everyday medical practice, especially for kidney function. Participants will be treated for 2 years at speciali…
Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for fabry patients with kidney failure: drug dosing study underway
Disease control OngoingThis study tests the safety and how the body processes migalastat in 14 adults with Fabry disease who have severe kidney impairment or are on dialysis. Participants take migalastat capsules, and researchers measure drug levels in blood and dialysate. The goal is to ensure proper …
Phase: PHASE3 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New york program offers extra screening for 100,000 newborns
Diagnosis ENROLLING_BY_INVITATIONScreenPlus is a large pilot program that offers families the option to have their newborn screened for a panel of rare genetic disorders, in addition to standard newborn screening. The study aims to screen 100,000 infants born at eight hospitals in New York. Researchers will eval…
Sponsor: Albert Einstein College of Medicine • Aim: Diagnosis
Last updated Jun 26, 2026 16:15 UTC
-
New vitamin supplements aim to make life easier for kids with rare metabolic disorders
Symptom relief OngoingThis study tests new vitamin and mineral supplements called EasiVits for children aged 1-16 with inborn errors of metabolism (IEM). These supplements have less carbohydrate and no flavor, so they can be used with different diets and kids can add their own taste. The goal is to se…
Phase: NA • Sponsor: NeoteriQ Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Exercise program aims to boost fitness in fabry patients
Symptom relief ENROLLING_BY_INVITATIONThis study is testing whether a 12-week physiotherapy and exercise program can improve physical fitness and quality of life in adults with Fabry disease. Fifteen participants will do regular exercise sessions using body weight, resistance bands, and increased daily activity. The …
Phase: NA • Sponsor: General University Hospital, Prague • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Hope for fabry pain: new drug trial targets nerve and belly discomfort
Symptom relief OngoingThis study tests whether venglustat can reduce nerve pain in the arms and legs, and belly pain, in people with Fabry disease. Participants are 16 or older and have not had Fabry treatment for at least 6 months. The trial lasts 12 months, with visits every 3 months, and compares v…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
NIH launches major study to unravel mysteries of rare genetic diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to identify genetic, biochemical, and clinical factors linked to disease severity in people with Gaucher disease and other lysosomal storage disorders. Researchers will evaluate up to 1,000 participants, including patients, carriers, and healthy controls, to bette…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Massive genetic study aims to unlock secrets of rare metabolic diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study will collect and analyze genetic data from 1000 people with suspected inherited metabolic diseases, including conditions like epilepsy and mitochondrial disorders. Researchers at Karolinska University Hospital aim to improve diagnosis by using advanced genetic testing …
Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Study on COVID-19 and metabolic disorders pulled before it began
Knowledge-focused TerminatedThis study was designed to track how COVID-19 infection might worsen the condition of people with inherited metabolic diseases (IMD). Researchers planned to collect information from French patients with IMD who had or had COVID-19 to see how often their metabolic disease got wors…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Taiwan study sheds light on rare fabry mutation and treatment effects
Knowledge-focused OngoingThis study follows 78 adults in Taiwan who have Fabry disease and carry a specific genetic mutation called GLA IVS4. Researchers are looking at how the disease affects the heart and other organs over time, both in people who have never been treated and those who have received aga…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Heart damage in fabry disease: new study tracks silent progression
Knowledge-focused OngoingThis study follows 31 Chinese adults with a specific genetic mutation (IVS4+919G>A) that causes Fabry disease, a condition where harmful substances build up and damage organs, especially the heart. Researchers use advanced heart scans and blood tests to track how the disease prog…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Home infusions may help patients stick to treatment
Knowledge-focused OngoingThis study looks at whether people with Fabry, Gaucher, or Hunter disease are more likely to continue their IV treatment when it's given at home versus at a hospital. Researchers will review existing data from 222 patients in Mexico. No new treatments are given; the goal is to un…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Fabry patients monitored in new enzyme therapy study
Knowledge-focused ENROLLING_BY_INVITATIONThis study watches 100 people with Fabry disease who are already taking enzyme replacement therapy as part of their regular care. Researchers want to see how the treatment affects their health over time by checking things like kidney function and pain levels. The study does not t…
Sponsor: NPO Petrovax • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC